HPS Pharmacies wish to advise that Echo Therapeutics are experiencing a supply interruption for Temgesic® sublingual tablets as follows:
Temgesic® Sublingual Tablets
Buprenorphine 200 microgram
ARTG 34091
This supply interruption currently only affects the 50-pack of sublingual tablets. Normal supplies of this product are expected to resume by the end of August 2025.
An internationally registered alternative of the 50-pack has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. This product is registered in Germany and labelling is in German. The strength is printed on the outer carton, but not on individual blisters, which may lead to confusion. To avoid this issue, the Australian-registered pack of 20 sublingual tablets may be considered, where appropriate.
Please note that S19A products may have a longer lead time as they must be sourced internationally.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Echo Therapeutics on 1300 848 328, or your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wish to advise of a supply issue affecting clopidogrel 75mg tablets.
Supplies of clopidogrel 75mg tablets are expected to be intermittent over the next 2-4 months. Normal supplies are expected to resume in September 2025 for some brands, while other brands are not expected to return until later in the year.
Combination products of clopidogrel 75mg + aspirin 100mg are currently available. However, supplies of some brands may also be impacted over this period.
Supplies of other antiplatelet agents (i.e. aspirin, prasugrel, and ticagrelor) have not been affected.
Retain this notice in a prominent position, including in other related business units, until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wish to advise that Amdipharm Mercury Australia is anticipating a supply interruption for Apresoline® Ampoules as follows:
Apresoline® Ampoules
Hydralazine hydrochloride 20mg
ARTG 43190
This supply interruption is expected to occur between mid-August 2025 and end-March 2026.
An internationally registered alternative has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. This stock is expected to be available from wholesalers from the second week of August 2025.
The S19A product is registered in Spain and labelling is in Spanish. Some of the other differences between the Australian registered product and the S19A alternative are shown in the table below.
| |
Apresoline® |
Hydrapres® |
| Status |
Australian-registered |
S19A product |
| Formulation |
Hydralazine 20mg |
Hydralazine 20mg
Also contains mannitol |
| Reconstitution |
Use 1mL WFI
Further dilute with NaCl 0.9% |
Use 1.1mL WFI but extract only 1mL |
The S19A product contains information on IM administration. Healthcare professionals are advised to ignore the reference to IM use and refer to the Australian Product Information (PI) for dosing and administration instructions. The Australian PI is supplied with the pack and also available here.
Please note that S19A products may have a longer lead time as they must be sourced internationally.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Amdipharm Mercury Australia on 1800 627 680, or your pharmacist at HPS Pharmacies.
Download PDF
Further to DrugAlert vol 1018, HPS Pharmacies wish to advise that Bridgewest is also experiencing a supply interruption for lidocaine 2% ampoules as follows:
Lidocaine Injection
Lidocaine (lignocaine) HCl 2% (400mg/20mL)
ARTG 49295
Lidocaine Injection
Lidocaine (lignocaine) HCl 2% (100mg/5mL)
ARTG 49293
Normal supplies of Bridgewest Lidocaine Injection 2% are expected to return in late February 2026.
Alternative brands of lidocaine 2% are available, including Lidocaine Apotex, Lidocaine Noridem, and Xylocaine. The approved indications and administration instructions may vary between brands. Please consult the product information for further details.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Bridgewest on (08) 9362 0666, or your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wish to advise that CSL Seqirus is experiencing a supply delay for Tiger Snake Antivenom® as follows:
Tiger Snake Antivenom®
Tiger Snake Antivenom 3,000 Units
ARTG 74895
Tiger Snake Antivenom® has been placed on constrained supply. All new orders will be assessed by CSL Seqirus and stock allocated manually. This may result in partial fulfilments or potentially delays in delivery.
In case of an urgent requirement, contact CSL Seqirus on 1800 008 275.
Normal supplies of Tiger Snake Antivenom® are expected to resume in mid-September 2025.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact CSL Seqirus on 1800 008 275, or your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wish to advise that Bridgewest is experiencing a supply interruption for lidocaine 1% ampoules as follows:
Lignocaine Injection
Lidocaine (lignocaine) HCl 1% (50mg/5mL)
ARTG 49296
Lignocaine Injection
Lidocaine (lignocaine) HCl 1% (200mg/20mL)
ARTG 49297
Normal supplies of Bridgewest Lidocaine Injection 1% 20mL are expected to return in mid-September 2025. Normal supplies of Bridgewest Lidocaine Injection 1% 5mL are expected to return in late August (boxes of 50) to early September 2025 (boxes of 5).
Alternative brands of lidocaine 1% are available, including Lidocaine Noridem, Lidocaine Accord, and Xylocaine. The approved indications and administration instructions may vary between brands. Please consult the product information for further details.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Bridgewest on (08) 9362 0666, or your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wishes to advise that Chiesi Australia is discontinuing Phospho-Soda Oral Solution as follows:
Phospho-Soda Oral Solution
Dibasic sodium phosphate + monobasic sodium phosphate
ARTG 283520
Phospho-Soda® Oral Solution is indicated for use as part of a bowel cleansing regimen in preparing adult patients for colon surgery or for preparing the colon for x-ray or endoscopic examination.
Many other orally administered bowel preparation products remain available, including:
- Glycoprep® sachets
- Moviprep® sachets
- Picolax® sachets
- Picoprep Orange® sachets
- Picosalax® sachets
- Plenvu® sachets.
Alternative enema preparations may also be considered in some cases.
Retain this notice in a prominent position, including in other related business units for at least one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Chiesi Australia on (03) 9077 4486 or your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wish to advise that both suppliers are experiencing a supply interruption for capecitabine 500mg tablets as follows:
Xelabine
Capecitabine 500mg
ARTG 213045
Capecitabine Sandoz
Capecitabine 500mg
ARTG 201800
This supply interruption is expected to be resolved by the end of July 2025.
An internationally registered alternative has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. This product is registered in the US and all labelling is in English.
Please note that S19A products may have a longer lead time as they must be sourced internationally.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
This notice only applies to the 500mg presentation. Capecitabine 150mg tablets are currently available.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Download pdf
HPS Pharmacies wish to advise that Pharmaco Australia is experiencing a supply interruption for Zyprexa® IM as follows:
Zyprexa IM® Vial
Olanzapine 10mg
ARTG 76867
This supply interruption is expected to be resolved by the end of July 2025.
An internationally registered alternative has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. This product is registered in the USA and all labelling is in English.
Please note that S19A products may have a longer lead time as they must be sourced internationally.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Pharmaco on 1800 201 564or your pharmacist at HPS Pharmacies.
Download PDF
HPS Pharmacies wish to advise that all suppliers are experiencing a supply interruption for prazosin 1mg and 2mg tablets, as follows:
| Product |
ARTG |
Estimated return date |
| APO-Prazosin 1 mg |
73858 |
End-August 2025 |
| APO-Prazosin 2 mg |
73862 |
End-August 2025 |
| Minipress 1 mg |
10756 |
End-January 2026 |
| Minipress 2 mg |
10757 |
End-January 2026 |
Minipress® 5mg tablets are currently available.
The Therapeutic Goods Administration (TGA) has authorised the supply of a Section 19A alternative for the 1mg and 2mg tablets. These products are registered in the USA and all labelling is in English. Both of the S19A alternatives are presented in capsule form (the Australian registered products are tablets).
Please note that S19A products may have a longer lead time as they must be sourced internationally.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Download PDF
